scholarly journals BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma

2021 ◽  
pp. MMT55
Author(s):  
Karam Khaddour ◽  
Tanner M Johanns ◽  
George Ansstas
Keyword(s):  
Metastatic Melanoma ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
High Dose ◽  
High Efficacy ◽  
Mek Inhibitors ◽  
Best Management ◽  
Improved Outcomes ◽  
Braf Mutant ◽  
Steroid Sparing

The introduction of immune checkpoint blockade (ICB) and BRAF-MEK inhibitors has substantially improved outcomes in patients with metastatic melanoma. However, several challenging factors may hinder the efficacy of ICB in patients with symptomatic intracranial metastatic melanoma who are immunosuppressed due to the use of steroids prior to the administration of ICB. This has resulted in the exclusion of patients treated with high dose steroid at baseline from the majority of ICB clinical trials. In addition, despite the high efficacy of BRAF-MEK inhibitors in BRAF-mutant intracranial metastatic melanoma, most tumors will eventually progress. This demonstrates a gap in addressing the best management in such patients. Here, we present a case demonstrating our approach in this patient population.

scholarly journals Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

2018 ◽  
Vol 24 (12) ◽  
pp. 1942-1942 ◽  
Author(s):  
Noam Auslander ◽  
Gao Zhang ◽  
Joo Sang Lee ◽  
Dennie T. Frederick ◽  
Benchun Miao ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Prediction Of Response ◽  
Robust Prediction

scholarly journals Current Advances in the Treatment of BRAF-Mutant Melanoma

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 482 ◽  
Author(s):  
Hima Patel ◽  
Nour Yacoub ◽  
Rosalin Mishra ◽  
Aaron White ◽  
Long Yuan ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Checkpoint Inhibitors ◽  
Mapk Pathway ◽  
Treatment Options ◽  
Individual Response ◽  
Term Survival ◽  
Mek Inhibitors ◽  
Development Of Resistance ◽  
Patient Responses ◽  
Braf Mutant

Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if detected early, however, treatment options for patients with metastatic melanoma are limited and the five-year survival rate for metastatic melanoma had been 15–20% before the advent of immunotherapy. Treatment with immune checkpoint inhibitors has increased long-term survival outcomes in patients with advanced melanoma to as high as 50% although individual response can vary greatly. A mutation within the MAPK pathway leads to uncontrollable growth and ultimately develops into cancer. The most common driver mutation that leads to this characteristic overactivation in the MAPK pathway is the B-RAF mutation. Current combinations of BRAF and MEK inhibitors that have demonstrated improved patient outcomes include dabrafenib with trametinib, vemurafenib with cobimetinib or encorafenib with binimetinib. Treatment with BRAF and MEK inhibitors has met challenges as patient responses began to drop due to the development of resistance to these inhibitors which paved the way for development of immunotherapies and other small molecule inhibitor approaches to address this. Resistance to these inhibitors continues to push the need to expand our understanding of novel mechanisms of resistance associated with treatment therapies. This review focuses on the current landscape of how resistance occurs with the chronic use of BRAF and MEK inhibitors in BRAF-mutant melanoma and progress made in the fields of immunotherapies and other small molecules when used alone or in combination with BRAF and MEK inhibitors to delay or circumvent the onset of resistance for patients with stage III/IV BRAF mutant melanoma.

Abstract 281: Evaluation of circular RNA profiling in metastatic melanoma patients treated with immune checkpoint blockade

2020 ◽  
Author(s):  
Juan Luis Onieva ◽  
Javier Oliver ◽  
Aurora Laborda-Illanes ◽  
Maria Rosario Chica-Parrado ◽  
Alicia Garrido-Aranda ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Immune Checkpoint ◽  
Circular Rna ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Rna Profiling ◽  
Melanoma Patients

Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Cristel Ruini ◽  
Carolin Haas ◽  
Sebastian Mastnik ◽  
Maximilian Knott ◽  
Lars E. French ◽  
...  
Keyword(s):  
Primary Biliary Cirrhosis ◽  
Metastatic Melanoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Biliary Cirrhosis ◽  
Granulomatous Hepatitis

scholarly journals Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Thilo Gambichler ◽  
Stefanie Strutzmann ◽  
Andrea Tannapfel ◽  
Laura Susok
Keyword(s):  
Metastatic Melanoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series

2016 ◽  
Vol 66 (1) ◽  
pp. 113-117 ◽  
Author(s):  
Lavinia Spain ◽  
Gerard Walls ◽  
Christina Messiou ◽  
Samra Turajlic ◽  
Martin Gore ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Immune Checkpoint ◽  
Case Series ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade
Sign in / Sign up

Export Citation Format

Share Document